The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorGeneral Hospital of Shenyang Military Region

About this trial

Intracranial atherosclerotic disease is the most common cause of ischemic stroke that is directly attributed to the progression or rupture of intracranial high-risk plaque in Asia. Many studies mainly from Euro-American population with a focus on extracranial carotid plaque have fully demonstrated the advantages of intensive statin therapy on stabilizing or reversing plaque burden, reversing plaque composition presenting that lipid-rich necrotic core (LRNC) is gradually replaced by fibrous tissue, and even reversing pattern of arterial remodeling to reduce the occurrence of cerebrovascular events. Yet, direct evidence of the effect of intensive statin therapy on intracranial atherosclerotic plaques is lacking and the effect of statin intensity and duration on intracranial plaque burden and composition is still unclear. High resolution magnetic resonance imaging (HRMRI) is a new and non-invasive technique that enable to assess the morphologic characteristics of vascular wall and plaque composition of intracranial artery. Based on above discussion, the investigators conduct this study to further determine the effect of intensive statin in ischemic stroke with intracranial atherosclerotic plaques.

Eligibility criteria

Qualifiers

Patient age between 18-80 years

Time of onset: within 1 week

NIHSS score ≤12

Acute ischemic stroke confirmed by head CT or MRI

Disqualifiers

Intracranial hemorrhage found by head CT

Stroke attributable to cardioembolic origin (atrial fibrillation, valvular heart disease, aortic arch atherosclerosis)

Severe hepatic or renal dysfunction

Pregnant females

Trial design

Treatments tested in this trial

  • Atorvastatin Calcium
  • Atorvastatin Calcium
  • Probucol
  • PCSK9 inhibitor

Treatment groups

100 Participants
are divided into 2 treatment groups